These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 29084469)

  • 1. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
    Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
    Tang JT; Andrews LM; van Gelder T; Shi YY; van Schaik RH; Wang LL; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):555-65. PubMed ID: 27010623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells.
    Lemaitre F; Blanchet B; Latournerie M; Antignac M; Houssel-Debry P; Verdier MC; Dermu M; Camus C; Le Priol J; Roussel M; Zheng Y; Fillatre P; Curis E; Bellissant E; Boudjema K; Fernandez C
    Clin Biochem; 2015 Apr; 48(6):406-11. PubMed ID: 25562187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
    Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
    Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.
    Zhang X; Lin G; Tan L; Li J
    Biomed Pharmacother; 2018 Jun; 102():107-114. PubMed ID: 29550633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management.
    Shuker N; van Gelder T; Hesselink DA
    Transplant Rev (Orlando); 2015 Apr; 29(2):78-84. PubMed ID: 25687818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
    Ware N; MacPhee IA
    Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
    de Jonge H; Naesens M; Kuypers DR
    Ther Drug Monit; 2009 Aug; 31(4):416-35. PubMed ID: 19536049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    van Gelder T; Hesselink DA
    Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients.
    Tron C; Woillard JB; Houssel-Debry P; David V; Jezequel C; Rayar M; Balakirouchenane D; Blanchet B; Debord J; Petitcollin A; Roussel M; Verdier MC; Bellissant E; Lemaitre F
    PLoS One; 2020; 15(3):e0230195. PubMed ID: 32163483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives.
    Degraeve AL; Moudio S; Haufroid V; Chaib Eddour D; Mourad M; Bindels LB; Elens L
    Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):769-782. PubMed ID: 32721175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meltdose Tacrolimus Pharmacokinetics.
    Baraldo M
    Transplant Proc; 2016 Mar; 48(2):420-3. PubMed ID: 27109969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
    Fukudo M
    Yakugaku Zasshi; 2007 Jul; 127(7):1081-9. PubMed ID: 17603267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
    Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome.
    Kuypers DRJ
    Clin Pharmacol Ther; 2020 Feb; 107(2):347-358. PubMed ID: 31449663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2004; 43(10):623-53. PubMed ID: 15244495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.